AKBA Q1 2021 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$52M-40.9% YoY

Gross Profit

$18M33.8% margin

Operating Income

-$65M-124.2% margin

Net Income

-$70M-133.0% margin

EPS (Diluted)

$-0.45

QoQ Revenue Growth

-7.8%

Cash Flow

Operating Cash Flow

-$71M

Free Cash Flow

-$71M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$629M

Total Liabilities

$415M

Stockholders' Equity

$214M

Cash & Equivalents

$253M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$52M	$88M	-40.9%
Gross Profit	$18M	$61M	-70.9%
Operating Income	-$65M	-$59M	-9.8%
Net Income	-$70M	-$61M	-14.5%

Revenue Segments

Product

$30M58%

License Collaboration And Other Revenue

$22M42%